Lv52
1366 积分 2023-12-25 加入
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
16小时前
待确认
Multiple myeloma
1天前
待确认
Reducing economic burden and improving quality of life in pulmonary arterial hypertension
9天前
已完结
Medication Non-Adherence in Patients with Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry (PHAR)
13天前
已完结
Impact of the COVID‐19 pandemic on chronic disease management and patient reported outcomes in patients with pulmonary hypertension: The Pulmonary Hypertension Association Registry
13天前
已完结
Pulmonary hypertension
13天前
已完结
Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma
14天前
已完结
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
14天前
已完结
Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network
15天前
已完结
SOHO State of the Art Updates and Next Questions | Manuscript Title: Bispecific T-Cell Engagers: Sequencing, B-Cell Maturation Antigen, GPRC5D, and Resistance
16天前
已关闭
皖公网安备34019202002308
